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Nanoencapsulation of ABT-737 and camptothecin
enhances their clinical potential through synergistic
antitumor effects and reduction of systemic toxicity
D Schmid1,2, GE Jarvis3, F Fay1,5, DM Small4, MK Greene1, J Majkut2, S Spence4, KM McLaughlin2, KD McCloskey2, PG Johnston2,
A Kissenpfennig4, DB Longley2,6 and CJ Scott*,1,2,6
The simultaneous delivery of multiple cancer drugs in combination therapies to achieve optimal therapeutic effects in patients can
be challenging. This study investigated whether co-encapsulation of the BH3-mimetic ABT-737 and the topoisomerase I inhibitor
camptothecin (CPT) in PEGylated polymeric nanoparticles (NPs) was a viable strategy for overcoming their clinical limitations and
to deliver both compounds at optimal ratios. We found that thrombocytopenia induced by exposure to ABT-737 was diminished
through its encapsulation in NPs. Similarly, CPT-associated leukopenia and gastrointestinal toxicity were reduced compared with
the administration of free CPT. In addition to the reduction of dose-limiting side effects, the co-encapsulation of both anticancer
compounds in a single NP produced synergistic induction of apoptosis in both in vitro and in vivo colorectal cancer models. This
strategy may widen the therapeutic window of these and other drugs and may enhance the clinical efficacy of synergistic drug
combinations.
Cell Death and Disease (2014) 5, e1454; doi:10.1038/cddis.2014.413; published online 9 October 2014
Colorectal cancer is the third most commonly occurring cancer
worldwide. Despite advances in understanding the molecular
basis of the disease and development of new therapeutic
modalities, the 5-year overall survival for patients with late-
stage disease remains poor.1 Although new compounds are
continually developed, the lack of efficacy at systemically
tolerable doses frequently precludes their success in the clinic.
Formulation and delivery strategies that can improve the
narrow therapeutic window of such compounds have the
potential to make significant advances in treatment regimens.
ABT-737 is a small molecule that targets the BH3-binding
hydrophobic cleft of antiapoptotic B-cell lymphoma (Bcl)
proteins Bcl-2, Bcl-w and Bcl-X(L), which are frequently
upregulated in tumors and strongly associated with
chemoresistance.2 As a single agent, ABT-737 is particularly
potent against leukaemia/lymphoma cells and a range of
small-cell lung carcinomas, causing complete regression of
solid tumors in mouse models.3 Moreover, its orally bioavail-
able derivative, ABT-263, has shown potential clinical utility in
combination therapies as it has been demonstrated to
sensitize tumor types, including colorectal cancer cells, to a
range of chemotherapies.4 However, the clinical evaluation of
ABT-263 has revealed that its therapeutic effects are
compromised by severe dose-dependent thrombocytopenia.5–7
Platelets normally survive in circulation for several days by
maintaining elevated levels of Bcl-X(L), the inhibition of which
by ABT-263/ABT-737 results in premature initiation of platelet
apoptosis.8,9 In spite of these issues, ABT-263 is still under
clinical investigation in combination with frontline cytotoxic
chemotherapies such as irinotecan and other therapies
(Supplementary Table S1).
Camptothecin (CPT) is a potent topoisomerase-I inhibitor;
however, it is poorly soluble and rapidly hydrolyzed from
a lactone to an inactive carboxylic acid in an aqueous
environment, thus limiting its clinical applicability. Conse-
quently, this has led to the development of derivatives such as
irinotecan.10 Although irinotecan overcomes some of the
pharmacokinetic problems associated with CPT, it has
reduced inhibitory activity and still exhibits systemic toxicities
such as neutropenia and dose-limiting diarrhea owing to the
damage of the intestinal mucosa.11
Pharmaceutical formulations that improve the safety profile
of potent anticancer drugs such as ABT-737/263 and CPTare
urgently required. Drug-loaded nanotherapeutics are finding
increasing application in a range of solid tumors, best
exemplified by Doxil, a liposomal preparation of doxorubicin
that reduces drug-associated myocardiotoxicity.12 Such drug
carriers can not only diminish adverse effects, but also
simultaneously enhance tumor localization through the ability
of nanosized particles to penetrate defective endothelial
junctions in the tumor neovasculature – a phenomenon known
as the enhanced permeability and retention (EPR) effect.13 Of
1School of Pharmacy, Queen’s University Belfast, Belfast, UK; 2Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK; 3Department of
Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK and 4Centre for Infection and Immunity, Queen’s University Belfast, Belfast, UK
*Corresponding author: CJ Scott, School of Pharmacy, Queen’s University Belfast, 97 Lisburn Road BT9 7BL, Belfast, UK. Tel: +44 0 28 9097 2350;
Fax: +44 0 28 9024 7794; E-mail: c.scott@qub.ac.uk
5Current address: Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
6These authors contributed equally to this work.
Received 9.6.14; revised 28.8.14; accepted 29.8.14; Edited by A Stephanou
Abbreviations: CPT, camptothecin; PLGA, poly-lactide-co-glycolide acid; PEG, polyethylene glycol; NP, nanoparticle; GI, gastrointestinal; MPS, mononuclear
phagocyte system
Citation: Cell Death and Disease (2014) 5, e1454; doi:10.1038/cddis.2014.413
& 2014 Macmillan Publishers Limited All rights reserved 2041-4889/14
www.nature.com/cddis
note, a polymeric formulation of CPT, CRLX101, has been
clinically evaluated, and it was demonstrated that the
improved pharmacokinetics and tumor penetration of nano-
particle (NP)-based carriers observed in mouse models were
maintained in patients,14 highlighting the therapeutic potential
that new formulations hold for this parental molecule.
Previously, we developed polymeric NPs encapsulating a
range of drug types, formulated in FDA-approved poly-lactide-
co-glycolide acid (PLGA).15–17 In the current investigation, we
wished to examine the application of both CPTand ABT-737 in
colorectal cancer models and determine if a nanodelivery
system could be employed to elicit the synergistic efficacies of
these agents. We show that nanoencapsulation of ABT-737
reduces thrombocytopenic effects, whereas nanoencapsula-
tion of CPT inhibits its cytotoxic effects towards white blood
cells and the gastrointestinal (GI) tract. Both drugs were
successfully combined in a single NP formulation to elicit
synergistic effects against colorectal cancer cells in vitro and
in vivo; this highlights the potential of this approach and similar
formulations for widening narrow therapeutic windows for the
treatment of colorectal and other cancers with rationally
selected drug combinations delivered at pre-determined
synergistic concentrations.
Results
Characterization of CPT-loaded NPs. The objective of this
study was to develop a stealth polymeric drug delivery
system that would enable the entrapment of CPT and/or
ABT-737 within the hydrophobic PLGA core (Figure 1a).
Previous work has shown that the introduction of a hydro-
philic polyethylene glycol (PEG) corona on the surface of
PLGA NPs can enhance their circulation time by reducing
protein adsorption and NP uptake by the mononuclear
phagocyte system (MPS).18 PEG NPs formulated with 25%
(w/w) mPEG5000-PLGA were of similar size compared with
non-PEGylated NPs (Table 1, row 1 and 2, Supplementary
Figure S1a), yet elicited reduced in vitro macrophage uptake
by up to 70% (Supplementary Figure S1b). CPT was
encapsulated in both formulations and the NPs were
Figure 1 Characterization of CPT-loaded NPs. (a) Schematic of drug-loaded PEG-PLGA NPs. (b) SEM images of CPT-loaded PLGA and PEG-PLGA NPs, scale bar
represents 100 nm. (c) Flow cytometric cell cycle analysis (RNase A/PI staining) of murine colorectal MC38 cancer cells following treatment with different CPT formulations
(0.12 μM) for 24 h. (d) Cell viability of MC38 cells following treatment with different CPT formulations for 48 h was assessed by MTT assay, mean± S.E.M., n= 3
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analyzed for size, polydispersity (Table 1, rows 3 and 4) and
morphology (Figure 1b), revealing an overall uniform popula-
tion, with only a minor increase in size and polydispersity
compared with non-drug loaded ‘blank’ NPs. To ensure that
the entrapped drug remained active, the formulations
were analyzed for their cytotoxic effects. MC38 murine
colorectal cancer cells were incubated with either free
CPT or CPT-loaded NPs. Cell cycle analysis after
24 h incubation showed that cells treated with CPT,
whether nanoformulated or not, similarly induced S-phase
delay and cell cycle arrest in the G2/M phase (Figure 1c).
After 48 h, all CPT formulations reduced cell viability
in a dose-dependent manner, with comparable EC50 for all
three formulations of between 0.12 and 0.17 μM (Figure 1d),
whereas blank NPs did not impact on cell viability at the
highest polymer concentrations (Supplementary Figure S1c).
Similar effects with the different CPT formulations were
observed against the human colorectal cancer cell line
HCT116 (Supplementary Figure S2).
Nanoencapsulated CPT reduces tumor volume and
chemotherapy-associated side effects. To investigate the
effects of the different CPT formulations on in vivo antitumor
activity, equivalent amounts of CPT as free drug, encapsu-
lated in NPs or PEG NPs were administered intravenously on
days 6, 10 and 14, respectively, to mice bearing syngeneic
MC38 tumors. CPT as free drug and formulated in PEG NPs
significantly inhibited the growth of these rapidly growing,
aggressive murine tumors by ~30% on day 17; unPEGylated
CPT NPs also inhibited tumor growth; however, this failed to
reach significance (Figure 2a and Supplementary Figure
S3a). These growth-inhibitory effects correlated with
enhanced apoptotic events, as the number of TUNEL-
stained cells was increased in the tumor tissue for all CPT
formulations on day 18 when the study was terminated
(Figure 2b and Supplementary Figure S3b). Although all mice
appeared healthy without significant weight loss during the
study (Figure 2c), the analyses of their blood revealed that
free CPT and CPT NPs significantly reduced the numbers of
circulating white blood cells, whereas the delivery of CPT in
PEG NPs conferred protection against this toxic side effect
(Figure 2d and Supplementary Figure S3c). Moreover, there
was a clear indication that the nanoencapsulation of CPTwas
able to reduce the microvilli destruction in the jejunum that
was induced by free-drug administration as shown by TUNEL
and haematoxylin and eosin (H&E) staining (Figure 2e).
Collectively, these data indicate that CPT encapsulated in
PEG NPs exhibits similar antitumor effects compared with
free drug, but significantly reduces the systemic toxicity of
CPT toward white blood cells and the GI tract.
Nanoencapsulation of ABT-737 reduces thrombocytopenic
effects. The same formulation approach was then used
to prepare ABT-737-loaded PEG NPs. ABT-737 is particularly
hydrophobic (logP47) and it was readily entrapped in the
NPs, with ‘low drug content’ used for initial in vitro analysis
and, subsequently, ‘high drug content’ NPs necessary to
achieve therapeutic dosages during in vivo assessment
(Table 1, rows 5 and 8). The in vitro analyses confirmed that
the drug was similarly potent against the HCT116 cells
whether nanoformulated or not, with an EC50 of 6.6± 0.9 μM
for free ABT-737 and 8.9±1.0 μM for the NP formulation
(Figure 3a). Further analysis highlighted that free and
encapsulated ABT-737 induced activation of downstream
caspases 3 and 7 that was apparent within the first 6 h
following treatment, confirming an apoptotic mechanism of
cell death (Figure 3b).
We postulated that the encapsulation of ABT-737 in
these PEGNPsmay protect platelets from its cytotoxic effects.
The incubation of human platelets with free ABT-737 induced
the inhibition of platelet aggregation over time; in contrast, the
encapsulation of ABT-737 in PEG NPs significantly abrogated
platelet toxicity in vitro (Figure 3c). This effect was
then examined in vivo as ABT-737 was administered either
as a free drug or encapsulated in PEG NPs. Initial platelet
counts were no different between the three treatment
groups in the model with the highest Schwarz Bayesian
Criterion (SBC) (Figure 3d). Both the ABT-737 treatment
groups showed a reduction in platelet count, whereas the
control group did not. However, the encapsulation of ABT-737
significantly altered the kinetics of the reduction in platelet
counts (Po0.0001). This effect was best characterized as a
177-fold reduction in the rate constant (k) rather than as
a change in the extent of the effect. Taken together, these data
demonstrate that ABT-737 remains active following nanofor-
mulation, but its platelet toxicity is attenuated as a result of
encapsulation.
Table 1 Drug loading (per mg of polymer), size and polydispersity index (PDI) of CPT- and/or ABT-737-loaded NPs, mean±S.D., n≥ 4
Formulation ABT-737 (μg/mg) CPT (μg/mg) Polymer Size (nm)a PDIa
1 — — PLGA 181± 13 0.06±0.04
2 — — PEG-PLGA 160± 14 0.07±0.04
3 — 26±5 PLGA 203± 19 0.21±0.11
4 — 26±1 PEG-PLGA 187± 5 0.14±0.04
5 33± 6 — PEG-PLGA 166± 11 0.10±0.07
6 — 2.9±0.3 PEG-PLGA 173± 7 0.09±0.09
7 34± 6 1.8±0.7 PEG-PLGA 169± 12 0.06±0.02
8 263± 26 — PEG-PLGA 212± 7 0.11±0.10
9 — 12±2 PEG-PLGA 197± 4 0.17±0.05
10 273± 17 12±2 PEG-PLGA 212± 10 0.12±0.05
aMeasured in PBS
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Co-encapsulated ABT-737 and CPT exhibit synergistic
activity against colorectal cancer cell lines. As a single
agent, the clinical activity of ABT-263 has been relatively
modest, particularly in solid tumors,5,6 and therefore its
therapeutic utility in combination therapies has been
explored. To investigate the combined effectiveness of its
parental molecule ABT-737 and CPT, the drugs were co-
administered to HCT116 cells, and cytotoxicity determined.
Co-incubation with both free drugs revealed synergistic
cytotoxic effects, with combination indices of o1 at a broad
range of concentrations when ABT-737 was in molar excess
to CPT (Figures 4a and b). The drug combinations resulted in
markedly enhanced induction of apoptosis as determined by
PARP cleavage, which was apparent in ABT-737 and CPT co-
treated cells at concentrations at which neither agent alone
induced apoptosis (Figure 4c).
Having established that ABT-737andCPTproduce synergistic
proapoptotic effects in HCT116 cells, the potential of translating
these effects by generating dual-loaded PEG NP was investi-
gated. Co-encapsulation and control NP formulations were
generated for in vitro studies with a molar drug ratio CPT:
ABT-737 of ~1 : 8 (Table 1, rows 5, 6 and 7). Similar to free drugs,
the dual-loaded NPs exhibited synergistic cytotoxic effects
toward HCT116 cells at a range of NP concentrations, with CI
values as low as 0.3 (Figure 5a). Treatment of HCT116 cells with
these NPs resulted in supra-additive increases in caspase 3/7
activity within 12 h of treatment (Figure 5b). This chemosensitiz-
ing effect was also revealed by markedly increased PARP
cleavage for the dual-loaded particles over single-agent control
formulations (Figure 5c). Similar effects were observed in two
other colorectal cancer cell lines (Figures 5b and c); the RKO
cells showedmarkedly enhanced caspase3/7 activitywithin 12 h
of incubation and PARP cleavage at drug concentrations that
were ineffective on their own. The HT29 cell line was generally
less sensitive to treatment with these agents, and longer
incubation (48 h) and higher doses were required to induce a
significant apoptotic phenotype.
Molecular insights into the synergistic action of ABT-737
and CPT. In addition to the activation of executioner
caspases 3/7 following treatment with dual-loaded NPs
(Figure 5), there was also enhanced activation of initiator
caspase 9 (indicative of activation of the intrinsic apoptotic
pathway) and caspase 8 (indicative of the activation of the
extrinsic apoptotic pathway) in all the three cell lines
(Figure 6a). By modulating the transcription of a number of
pro- and antiapoptotic genes, p53 regulates both the intrinsic
and extrinsic apoptotic pathways and was potently upregu-
lated in response to CPT (but not ABT-737) in the two p53
wild-type cell lines HCT116 and RKO (Figure 6b). Interest-
ingly, the R273H mutant p53 expressed in HT29 cells was
also upregulated in response to CPT; this common p53
mutant appears to retain some wild-type activity (unpublished
observations). Bcl-2 expression was downregulated in
response to CPT in both HCT116 and RKO cell lines,
whereas Bax was upregulated in all the three cell lines.
Figure 2 Growth inhibition of syngeneic colorectal tumors and reduction of chemotherapy-associated adverse effects through CPT nanoencapsulation. (a) MC38 colorectal
tumor volume on day 17 after cell inoculation in C57BL/6 mice and serial treatment with CPT (2.5 mg/kg) on day 6, 10 and 14, mean± S.E.M., n≥ 8. (b) Quantification of TUNEL-
positive cells analyzed in isolated tumors, mean± S.E.M., n= 3. (c) Mouse body weight during the treatment regime, mean± S.E.M., n≥ 8. (d) Quantification of circulating white
blood cells (WBC) analyzed by flow cytometry as %WBC of parental population, mean± S.E.M., n≥ 8. (e) Images of paraffin-embedded sections of the jejunum stained with H&E
or TUNEL after serial CPT treatment, representative scale bar equals 100 μm
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Another p53-dependent gene, Noxa was also up-regulated in
response to CPT. Bcl-X(L) was unchanged in all the
treatment groups, whereas Bak expression was moderately
upregulated in cells treated with CPT. In addition, both wild-
type and mutant forms of p53 can promote apoptosis at a
post-transcriptional level by interacting with key proteins of
the intrinsic pathway such as Bcl-2, Bcl-X(L), Mcl-1 and
Bax.19,20 Thus, the increased p53 protein expression induced
by CPT may promote activation of proapoptotic Bcl-2 family
members, thereby facilitating ABT-737-induced apoptosis.
ABT-737 and ABT-263 do not inhibit Mcl-1, and increased
Mcl-1 expression is a major resistance mechanism to ABT-
737/263.21,22 We found that ABT-737 treatment acutely
increased Mcl-1 expression in HCT116 and HT29 cells, but
not RKO cells, which already expressed Mcl-1 at high levels
(Figure 6b). CPT treatment had varying effects on Mcl-1
expression, with no effect in HT29 cells, increased expression
in HCT116 cells and decreased expression in RKO cells. In
CPT/ABT-737-co-treated cells, Mcl-1 expression was higher
(HCT116 and HT29) or similar (RKO) to untreated cells,
suggesting that the mechanism of synergy between CPTand
ABT-737 is not dependent on the downregulation of Mcl-1
expression. FLIP is a major regulator of the extrinsic apoptotic
pathway through its ability to inhibit death receptor-mediated
activation of caspase-8.23 Interestingly, CPT treatment at this
concentration resulted in increased expression of the major
FLIP splice form FLIP(L), and this was attenuated in cells co-
treated with CPTand ABT-737 (Figure 6b).We have previously
reported that FLIP is a major inhibitor of chemotherapy-
induced apoptosis;24,25 therefore, attenuation of FLIP(L)
upregulation in response to CPT in cells co-treated with
ABT-737 is likely to promote caspase-8 activation (Figure 6a)
and apoptosis induction.
Synergistic growth-inhibitory effects in HCT116 xenograft
model. To achieve appropriate drug doses for in vivo
evaluation, NP formulations with high drug loading were
prepared and analyzed while maintaining the synergistic drug
ratio of CPT:ABT-737 close to 1 : 10 (Table 1, rows 8, 9 and
10). These formulations were then used to treat developing
HCT116 xenografts. Each drug treatment was given four
times between days 8 and 20. Tumor growth analyses
revealed that the single-agent ABT-737 NPs did not elicit
significant antitumor effects compared with the control arms,
whereas mice treated with CPT-only NPs did demonstrate
significantly reduced tumor development. Despite its lack of
Figure 3 Nanoencapsulation of ABT-737 inhibits thrombocytopenic effects. (a) Dose–response curves of HCT116 cells after treatment with free or PEG-PLGA encapsulated
ABT-737 for 48 h assessed by MTT cell viability assay, mean± S.E.M., n= 3. (b) Caspase 3/7 activity in HCT116 cells after treatment with free and nanoencapsulated ABT-737
(5 μM) for 6 h, relative to control treated cells, mean± S.E.M., n= 4. (c) Aggregometry of washed human platelets after pre-incubation with free or nanoencapsulated ABT-737
(1 μM), platelet aggregation was induced by U46619 (2 μM), mean±S.E.M., n= 4. (d) Time course of platelet counts in C57BL/6 mice following intraperitoneal injection of
50 mg/kg of free ABT-737 or ABT-737 NPs, n≥ 5. A significant difference was observed between the two ABT-737 treatment groups (Po0.0001).The best fit model (highest
Schwarz Bayesian Criteria=− 398.2) indicated a difference in the rate of change by ~ 177-fold
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efficacy as a single agent, ABT-737 co-encapsulated with
CPTenhanced antitumor activity compared with the CPT-only
NPs (Figure 7a). Without any further treatment from day 20,
the median survival was enhanced by 8.5 days when
500mm3 tumor volume was used as the study end point for
survival analysis (Figure 7b). Although the treatment with
CPT-only NPs induced some weight loss (~10%) in the
animals, these effects were not severe, and, importantly,
despite the enhanced antitumor effects of co-encapsulated
CPT and ABT-737, further weight losses were not observed
(Figure 7c).
Discussion
This work demonstrates the ability to reduce toxic side-effects
that are associated with the anticancer therapeutics CPTand
Figure 4 Synergistic effects of free ABT-737 and CPTon colorectal cancer cells. (a) Affected (non-viable) cell fractions following treatment of HCT116 cells with ABT-737, CPT
and both drugs in combination for 48 h assessed by MTT cell viability assay, mean± S.E.M., n= 3. (b) Combination indices calculated from cell viability data in (a), mean± S.E.
M., n= 3. (c) Effect of drug combinations on PARP cleavage in HCT116 cells after 24 h incubation
Figure 5 Synergistic effects of ABT-737 on CPT-induced cytotoxicity against colorectal cancer cell lines achieved by co-encapsulation in PEG-PLGA NPs. (a) Combination
indices obtained from MTT cell viability data following treatment of HCT116 cells with a range of polymer concentrations for 48 h, mean± S.E.M., n= 3. (b) Caspase 3/7 activity
following treatment of different colorectal cancer cell lines with ABT-737 (4 μM) or CPT (500 nM) in single- or dual-loaded NPs, mean± S.E.M., n≥ 3. (c) Effect of NP formulations
on PARP cleavage in HCT116 cells following treatment for 24/48 h
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ABT-737 by encapsulating them in PEGylated polymeric NPs.
Furthermore, the combination of both agents in a single NP
formulation was found to produce synergistic antitumor effects
against a preclinical model of colorectal cancer.
Although both ABT-737/263 and CPT have been super-
seded by derivatives such ABT-199 and irinotecan, these
parental molecules are still under clinical evaluation
(Supplementary Table S1),14 and, owing to their low water
solubility, they are particularly suitable for encapsulation into
PLGA-based systems. However, the hydrophobic nature of
PLGA can also induce the adsorption of plasma proteins to the
NP surface, which promotes their clearance by the MPS.26
The incorporation of a hydrophilic PEG corona has previously
been found to alleviate this clearance,27 and therefore we
developed PEG-PLGA NPs with a total of 8% (w/w) PEG. The
incorporation of this proportion of PEG sufficiently reduced
macrophage uptake, consistent with previous reports identify-
ing an optimal range of 5–10% PEG.28,29
Taking this optimized drug carrier formulation forward, we
initially considered the potential of the NP to alleviate systemic
toxicities associated with our chosen drugs. Dose-limiting side
effects of chemotherapies such as leukopenia cause severe
challenges for the immune systems of patients.10,11 Upon
intravenous administration, we found that free CPT reduced
the number of white blood cells by up to two-thirds; the number
was also significantly reduced by CPT encapsulated in non-
PEGylated NPs. However, when administered in PEG NPs,
the deleterious effects of CPT on white blood cells were
abrogated. This suggests that the ability of the NPs to evade
the MPS through PEGylation may have a crucial role in
minimizing neutropenic effects. These findings are consistent
with recent clinical observations, in which a meta-analysis of
nine clinical trials concluded that the occurrence of neutrope-
nia is significantly reduced with liposomal doxorubicin
compared with conventionally delivered anthracyclines.30
Importantly, we also found clear evidence that encapsulation
of CPT in NPs reduces the damage to the GI tract caused by
the administration of free drug. GI toxicity found with CPT
derivatives is well-established and often requires supportive
care in the clinic.31 In agreement with our results, the first
clinical trials of NP-based delivery of various CPT-derived
drugs have reported no or rare grade 3 and 4 diarrhea.32–34
The on-target/off-tumor platelet toxicity of the BH3 mimetic
ABT-737 and its analogue ABT-263 has severely limited the
clinical utility of these agents.5–7 It has been demonstrated that
ABT-737 and ABT-263 reduce the ability of platelets to
aggregate by inducing apoptosis, which then results in their
rapid clearance.8,9,35 This dose-limiting side effect has been
shown to be due to the inhibition of Bcl-X(L) and has
subsequently led to the development of a Bcl-2-selective
inhibitor ABT-199.36 However, clinical interest in the inhibition
of multiple antiapoptotic proteins including Bcl-X(L) with
Figure 6 Molecular insights into the synergistic action of ABT-737 and CPT. (a) Caspase 9 and caspase 8 activity, mean± S.D., n= 3, and (b) western blot analysis of key
pro- and antiapoptotic proteins after treatment with the indicated doses of ABT-737 and CPT in single- or dual-loaded NPs for 24 h (HCT116, RKO) or 48 h (HT29)
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ABT-263/737 remains. Thus, the encapsulation of such
molecules is highly relevant to improve their clinical potential.
Here, it was shown that encapsulating ABT-737 into optimized
PEG NPs diminished its toxic effects toward platelets in vitro
and in vivo, while maintaining its proapoptotic anticancer
effects. Thus, the encapsulation of ABT-737 (or ABT-263) in
NPs could potentially circumvent the rapid drop in platelet
counts and thereby reduce dose-dependent thrombocytopa-
thy in the clinic, endowing this class of agent with a wider
therapeutic window. Moreover, compared with a Bcl-2-
selective inhibitor, NP-encapsulated ABT-737 is likely to be
more effective against tumors such as colorectal cancer that
frequently overexpress Bcl-X(L),37,38 the expression of which
was uniformly high in the three colorectal cancer models
assessed.
On account of the reduced toxicity observed with encapsu-
lated ABT-737 and CPT, both drugs were combined within one
formulation to generate a dual cytotoxic strategy. Only a limited
number of solid tumors are susceptible to apoptosis following
treatment with ABT-737/ABT-263 as a single agent, although it
is valued as a chemosensitizer in a range of solid tumors.3,4
Synergy was confirmed for both the free drugs in combination
and for the dual-loaded NPs, with CI values as low as 0.3.
Synergy of ABT-263 with a range of chemotherapies, including
CPT, was recently assessed, with average CI values of 0.47, in
agreement with our results.4
ABT-737 inhibits antiapoptotic Bcl-2, Bcl-X(L) and Bcl-w,
thus disrupting their interactions with proapoptotic BH3-only
proteins, which then activate Bax and Bak to induce
apoptosis.39,40 The tumor suppressor protein p53 is stabilized
by cell stress such as DNA damage caused by chemotherapy
and induces the transcription of proapoptotic Bax and Noxa as
well as repressing antiapoptotic Bcl-2,19,20 which is in
agreement with our observations following CPT treatment.
Noxa has been reported to be a critical determinant of
ABT-737 sensitivity in solid tumors,41 and its induction through
treatment with the CPT derivative CPT-11 has been shown to
sensitize colorectal cancer cells to ABT-737 . Moreover, it was
shown by Okumura et al.39 that Bax is essential for cytotoxic
effects of this combination therapy, and thus the increased
levels of Bax expression that we observed in response to CPT
may enhance the apoptotic effects of ABT-737. It was also
notable that the major inhibitor of the extrinsic apoptotic
pathway FLIP was upregulated in response to CPT at this
concentration, but this upregulation was abrogated in CPT/
ABT-737 co-treated cells. We have previously demonstrated
Figure 7 Chemosensitizing effect of ABT-737/CPT dual-loaded NPs against HCT116 xenografts. (a) HCT116 xenograft volume over time; the dashed lines indicate the days
of treatment with NPs containing 2.1 mg/kg CPT or 50 mg/kg ABT-737, mean± S.E.M., n≥ 6; significance was assessed in comparison to Blank NPs or between the two
treatment groups on day 28. (b) Kaplan–Meier survival analysis using 500 mm3 as the study end point. (c) Body weight over the time course, mean± S.E.M., n≥ 3
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that FLIP is a major inhibitor of chemotherapy-induced
apoptosis in colorectal cancer24,25 and is frequently over-
expressed in this disease.42
As a single agent, ABT-737 was shown to be ineffective at
inducing significant tumor growth inhibition in several xenograft
models of breast, colorectal and ovarian cancer at doses of
50mg/kg or more; however, it was shown to enhance the
antitumor effects of platinum-based chemotherapy and
docetaxel.43–45 Here, we observed similar results as the
treatment with ABT-737 NPs was ineffective against colorectal
xenografts, but synergistically chemo-sensitized the tumors to
treatment with CPT. Importantly, the synergistic drug ratio that
was established for in vitro experiments could successfully be
applied to the in vivo setting. In conclusion, the work presented
herein has shown that the systemic toxicities of CPT and
ABT-737 can be reduced by nanoencapsulation and that the two
drugs can be combined together in one NP to elicit improved
therapeutic effects. This chemosensitizing approach is applic-
able to combinations of other chemotherapeutics and molecu-
larly targeted agents. Indeed, the co-encapsulation of drug
combinations is an area of significant current interest.46,47
Importantly, NP formulations can achieve a level of passive
targeting of tumors through the EPR effect, enabling the delivery
of synergistic drug ratios, thereby overcoming problems caused
by differences in the pharmacokinetic profiles of individual
agents. Thus, this approach may represent an important
advance in current strategies to adminster combination che-
motherapies to cancer patients in the clinic.
Materials and Methods
NP preparation and characterization. All materials were supplied from
Sigma-Aldrich, Dorset, UK unless indicated otherwise. NPs were prepared by single
emulsion evaporation using PLGA 502H (Evonik Industries, Essen, Germany)
mixed with a 25% (w/w) blend of methoxy PEG5000-PLGA (mPEG5000-PLGA)
copolymer (AK10, 33% PEG content, Akina Inc., West Lafayette, IN, USA). The
polymer (20 or 30 mg in total) was dissolved in 1 ml of dichloromethane and added
into the aqueous phase containing 2.5% (w/v) polyvinyl alcohol in MES buffer
(50 mM, pH 5), sonicated in pulses for 90 s on ice and stirred overnight. ABT-737
(Biorbyt, Cambridge, UK, 65 μg/mg polymer in vitro, 333 μg/mg polymer in vivo)
and/or (S)-(+)-CPT (5 to 33 μg/mg polymer) was added into the organic phase
before emulsification. NPs were washed in MES buffer by three wash-spin cycles at
20 000 g. ABT-737 and CPT encapsulation was determined by absorbance at
420 nm and fluorescence at 380Ex/460Em nm, respectively. Particle size distribution
was measured in PBS by dynamic light scattering using a Zetasizer Nano ZS
(Malvern Instruments, Worcestershire, UK) and confirmed by scanning electron
microscopy (SEM, Jeol 6500 FEGscanning electron microscope, Akishima-Shi,
Japan).
Cell-based assays. The HCT116 cell line was kindly provided by Professor
Bert Vogelstein (Johns Hopkins University, Baltimore, MD, USA) and cultured in
McCoy medium supplemented with 10% FBS. RKO and HT-29 cells (LGC
Standards, Teddington, UK) were cultured in supplemented DMEM. HCT116, HT29
and RKO cell lines were validated by STR profiling by LGC Standards in May 2011.
All subsequent cells have only been taken from these validated stocks. The MC38
cell line was a gift from Dr. Steven Rosenberg (National Cancer Institute, NIH) and
cultured in supplemented DMEM. All cells were tested regularly for mycoplasma
contamination and found to be negative. Cells were seeded into 6-, 12- or 96-well
plates and left to adhere overnight. Cell viability was assessed by the addition of
MTT reagent (0.5 mg/ml). The resulting formazan crystals were dissolved in DMSO,
absorbance measured at 550 nm and cell viability expressed relative to PBS-treated
cells. Cell cycle progression was analyzed by flow cytometry (FACSCanto; BD,
Oxford, UK). Ethanol-fixed cells were incubated with propidium iodide (PI) and
RNase A (Qiagen, Manchester, UK) in PBS/1% FBS for 30 min. Cell lysates were
prepared using RIPA lysis buffer containing mini complete protease inhibitors
(Roche Applied Science, Penzberg, Germany) and the protein content was
determined using the BCA protein Assay Kit (Fisher Scientific, Loughborough, UK).
Caspase activity was analyzed in 5 μg of protein using Caspase Glo substrates
(Promega, Southampton, UK) and protein expression was assessed by SDS PAGE
and western blotting upon semi-dry protein transfer. The membrane was blocked
with 5% milk powder in TBS containing 0.1% Tween-20 and incubated with primary
antibodies overnight at 4 °C (Noxa, 1 : 250, from Merck Millipore, Feltham, UK; BAX
and Bcl-X(L), 1 : 1000 from Cell Signaling Technologies, Danvers, MA, USA; BAK,
Bcl-2, 1 : 1000 and p53, 1 : 5000 from Santa Cruz Biotechnology, Heidelberg,
Germany; Tubulin, 1 : 10 000 and Mcl-1, 1 : 1000 from Abcam, Cambridge, UK;
PARP, 1 : 5000 from eBioscience Ltd., Hatfield, UK; FLIP, 1 : 1000 from Adipogen,
Liestal, Switzerland). HRP-conjugated secondary antibody was added for 1 h and
the protein visualized by ECL Plus western blotting substrate (Fisher Scientific)
using the ChemiDoc XRS+ System (Bio-Rad, Hemel Hempstead, UK).
Platelet light transmission aggregometry. Ethical approval for the use
of blood from human volunteers was granted by the Ethical Committee of the School
of Pharmacy, Queen’s University Belfast. Human blood was drawn from healthy
drug-free volunteers by venepuncture into tri-sodium citrate. Washed platelets were
prepared at a concentration of 2 × 108 platelets/ml as previously described.48 Four
channel platelet aggregation profilers (PAP-4, Bio/Data Corporation, Horsham, PA,
USA) were used to assess platelet aggregation, which was induced by U46619
(2 μM). Data are presented as percentage of platelet aggregation obtained from the
recorded trace after 6 min.
In vivo experiments. All in vivo experiments were carried out in accordance
with the Animals (Scientific Procedures) Act, 1986, and approved by the
Department of Health, Social Services and Public Safety, Northern Ireland. Mice
were purchased from Harlan Laboratories, Bicester, UK, and maintained under
controlled environmental conditions (22 °C, 50± 10% relative humidity, 12-h light/
12-h dark cycle) with food/water ad libitum and under sterile conditions when
immunocompromised mice were used. A total of 5 × 105 MC38 murine colorectal
cancer cells were inoculated subcutaneously in the left flank of male C57BL/6 mice
(8–11 weeks old, 27± 2 g) using growth factor-reduced Matrigel (BD, diluted to
4 mg/ml in PBS). Mice were randomly assigned into groups and treated
intravenously via the tail vein with 2.5 mg/kg CPT or the equivalent amount of
CPT-loaded NPs. Free CPT was administrated as a formulation in PBS containing
DMSO and PEG400 (14 and 43% (v/v)). The study was terminated on day 18.
Blood was withdrawn via cardiac puncture into heparin solution and white blood cell
analysis carried out by flow cytometry after red blood cell lysis using OpiLyse B
solution (Beckman Coulter Ltd., High Wycombe, UK). The tumors and the GI tract
were dissected and fixed in 10% formalin before paraffin-embedding. Sections
(6 μm) were stained with Harris H&E (Fisher Scientific) or Terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) using the TumorTACS in situ Apoptosis
detection kit (Trevigen, Gaithersburg, MD, USA). Images were taken using an
Olympus BH2 microscope equipped with DP25 camera and × 10 objective lens, and
images were analyzed using Cell B software. TUNEL-positive cells were counted in
four fields of view of three tumors of randomly chosen mice.
To analyze the thrombocytopenic effect induced by ABT-737, male C57BL/6 mice
(9–12 weeks old, 26± 3 g) were injected once intraperitoneally with 50 mg/kg of
ABT-737 formulated as previously described49 (in 2.5% DMSO, 62.5% H2O
containing 5% dextrose, 5% Tween-80, 30% propylene glycol, (v/v), final pH 4.5) or
equal amounts of ABT-737-loaded NPs in PBS. Before, and 6, 24 and 48 h after the
injection, blood was withdrawn using EDTA-coated capillary tubes (Greiner Bio-One,
Kremsmünster, Austria) and the platelets were counted with a particle counter (50 μm
aperture, Beckman Coulter Ltd.).
To assess synergistic antitumor effects, 2 × 106 HCT116 cells were implanted
subcutaneously onto both flanks of female Balb/c nude mice (9–13 weeks, 19± 1 g)
using Matrigel and the mice were randomly assigned into treatment groups when the
tumors reached a volume of ~ 100 mm3. NP formulations were administered
intravenously into the tail vein encapsulating equivalents of 2.2 mg/kg CPT and/or
50 mg/kg ABT-737. Body weights were assessed regularly to ensure animal welfare
and the tumors were measured every 2–3 days using an electronic calliper calculating
the tumor volume according to: 0.5 × length × width2.
Data analysis. Bar and line graphs were plotted with Prism 5.01 software
(GraphPad software Inc., La Jolla, CA, USA) and statistical analysis was carried out
within. Analysis of variance (ANOVA) with Tukey post hoc test was used to
investigate statistical differences to compare several groups. The Student’s t-test
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was performed for comparison of the two groups. Significant differences are
denoted with *Po0.05; **Po0.01; ***Po0.001. Drug synergy was analyzed by
following the method of Chou and Talalay.50 To investigate thrombocytopenic effects,
data were modelled using NONMEM (ICON plc, Dublin, Ireland) to the following
structural model of limited exponential decline: Ct ¼ C0ekt þ C lim 1 ekt
 
,
where t is the time from administration (h); Ct the platelet count at
time t; C0 the platelet count when t=0; Clim the platelet count at limit
of drug effect; k the rate constant of decline (h−1). Data for the three
treatment conditions were fitted simultaneously using nine para-
meters. Model dimensionality was reduced by constraining para-
meters and identifying models with the highest Schwarz Bayesian
Criterion (SBC=LL—p ln(N), where LL is the maximized log like-
lihood, P the number of parameters in the model, and N the number
of data values).51 Specific hypotheses were evaluated using a
likelihood ratio test.52
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